Review Article
Position Statement on Secukinumab in the Management of Plaque Psoriasis: The Malaysian Perspective
Table 1
Dosing schedule and efficacy of secukinumab.
| Types of biologics | Dosing schedule [33] | Expected onset of clinical effect (week) [33] | Review of response (week) [33] | Efficacy at week 10 to 16 (PASI 75) [32] | Long-term efficacy [33] |
| Secukinumab | Subcutaneous, 300mg at week 0, 1, 2, 3, 4 and then every 4 weeks | 1 | 12 | 90.1% | PASI 75: 88.5% | PASI 90: 66.4% | PASI 100: 41.0% |
|
|